Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM; TRILOGY ACS Steering Committee..

Am Heart J. 2010 Jul;160(1):16-22.e1. doi: 10.1016/j.ahj.2010.04.022.

PMID:
20598967
2.

The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.

Toth PP.

Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955. Review.

PMID:
19179814
3.

Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.

Thomas D, Giugliano RP.

Crit Pathw Cardiol. 2009 Mar;8(1):12-9. doi: 10.1097/HPC.0b013e318196bb46. Review.

PMID:
19258833
4.

Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.

Baker WL, White CM.

Am J Cardiovasc Drugs. 2009;9(4):213-29. doi: 10.2165/1131209-000000000-00000. Review.

PMID:
19655817
5.

Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Capranzano P, Ferreiro JL, Angiolillo DJ.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):361-9. doi: 10.1586/erc.09.4. Review.

PMID:
19379060
6.

Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.

Martin MT, Spinler SA, Nutescu EA.

Clin Ther. 2011 Apr;33(4):425-42. doi: 10.1016/j.clinthera.2011.04.007. Review.

PMID:
21635989
7.

Critical review of prasugrel for formulary decision makers.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2009 May;15(4):335-43. Review.

8.

Antiplatelet intervention in acute coronary syndrome.

Arora RR, Rai F.

Am J Ther. 2009 Sep-Oct;16(5):e29-40. doi: 10.1097/MJT.0b013e31804c7238. Review.

PMID:
19092648
9.

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.

Mehta SR, Yusuf S.

J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):79S-88S. Review.

PMID:
12644345
10.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
11.

Optimizing platelet P2Y12 inhibition for patients undergoing PCI.

Steinhubl S, Roe MT.

Cardiovasc Drug Rev. 2007 Summer;25(2):188-203. Review. Erratum in: Cardiovasc Drug Rev. 2007 Autumn;25(3):299.

PMID:
17614940
12.
13.

Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.

Tcheng JE, Mackay SM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):83-91. doi: 10.2165/11594600-000000000-00000. Review.

PMID:
22316323
14.

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

Mousa SA, Jeske WP, Fareed J.

Clin Appl Thromb Hemost. 2010 Apr;16(2):170-6. doi: 10.1177/1076029609355589. Review.

PMID:
20299391
15.

[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].

Auer J, Berent R, Maurer E, Mayr H, Weber T, Eber B.

Herz. 2001 Mar;26(2):99-110. Review. German.

PMID:
11349620
16.

[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].

Abbate R, Crea F, De Servi S, Filippi E, Gensini GF, Golinos P, Savonitto S.

G Ital Cardiol (Rome). 2010 Feb;11(2):127-37. Review. Italian.

PMID:
20408476
17.

Thienopyridine antiplatelet agents: focus on prasugrel.

Freeman MK.

Consult Pharm. 2010 Apr;25(4):241-57. doi: 10.4140/TCP.n.2010.241. Review.

PMID:
20511177
18.

Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.

Jeong YH, Tantry US, Gurbel PA.

Expert Opin Pharmacother. 2012 Aug;13(12):1771-96. doi: 10.1517/14656566.2012.704909. Review.

PMID:
22783896
19.
20.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
Items per page

Supplemental Content

Support Center